In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Quiz|Articles|May 15, 2026
OncLive Weekly News Quiz (5/15/2026): Did You Catch 3 New FDA Oncology Approvals?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA granted accelerated approval to sonrotoclax (Beqalzi) for relapsed/refractory mantle cell lymphoma based on results from the phase 1/2 BGB-11417-201 trial (NCT05471843). What overall response rate was reported in patients previously treated with anti-CD20 therapy and a Bruton tyrosine kinase inhibitor?
Advertisement
Related to this article
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
A rituximab biosimilar has been approved by the FDA.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Sonrotoclax monotherapy produced durable responses in Chinese patients with relapsed/refractory mantle cell lymphoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
The OncFive: Top Oncology Articles for the Week of 8/9
3
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
4
Dr Viansone on De-Escalating Chemotherapy Type and Duration in HER2-Positive Breast Cancer
5